Moderna (MRNA) Revenue & Quarterly History
Explore Moderna, Inc. (MRNA) revenue from 2023 through the latest reported quarter, with SEC-sourced comparisons and filing-constrained analysis.
Key takeaway
Quarter ended Mar 31, 2026 · FY2026 Q1
Revenue for the quarter declined compared to the immediately preceding quarter but rose sharply versus the same quarter one year earlier. The year-over-year gain reflects a strong recovery from a low base in the prior year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$389M
Revenue reported for this quarter.
Quarter-over-quarter
-42.6%
Change from the immediately preceding quarter.
Year-over-year
+260.2%
Change from the comparable year-ago quarter.
Trailing four quarters
$2.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2025 | $142M | -41.1% |
| Sep 30, 2025 | $1B | -45.4% |
| Dec 31, 2025 | $678M | -29.8% |
| Mar 31, 2026 | $389M | +260.2% |
Revenue performance
Revenue decreased from the prior quarter, driven by lower sales volume. The sequential decline followed a trend of fluctuating quarterly revenue over the past four quarters.
Quarterly comparison
Compared to the immediately preceding quarter, revenue was lower. Relative to the same quarter one year earlier, revenue was substantially higher, marking a significant year-over-year improvement.
What to watch
Monitor the impact of a litigation settlement on cash flows and working capital, as noted in the filing.